4-Aminoquinoline derivatives as potent inhibitors of pancreatic cancer: Synthesis, evaluation and docking studies

•A set of twenty 4-aminoquinoline derivatives were synthesized and tested as inhibitors of pancreatic cancer.•Good anticancer activity with lowest IC50 value in MIA PaCa-2 cancer cells was observed.•Compound 3 g induces cell cycle arrest at the G2/M phase in a dose-dependent manner.•The docking stud...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of molecular structure 2024-09, Vol.1312, p.138677, Article 138677
Hauptverfasser: Chirra, Nagaraju, Begum, Habeebunnisa, Abburi, Naga Pranathi, Bollikanda, Rakesh Kumar, Murugesan, Periyasamy, Kantevari, Srinivas, Tangutur, Anjana Devi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•A set of twenty 4-aminoquinoline derivatives were synthesized and tested as inhibitors of pancreatic cancer.•Good anticancer activity with lowest IC50 value in MIA PaCa-2 cancer cells was observed.•Compound 3 g induces cell cycle arrest at the G2/M phase in a dose-dependent manner.•The docking studies of 3 g revealed the best molecular interactions with cyclooxygenase-2 (PDB ID: 1CX2).•The scaffold is unexplored and offers wide scope for structural optimization and drug development. Herein we describe synthesis and evaluation of 4-aminoquinoline derivatives as anticancer agents. By using Friedlander type condensation and cyclization reactions, the new compounds were synthesized in one-pot from commercially available anthranilonitriles and substituted acetophenones in excellent yields. All the new compounds were purified, fully characterized, and evaluated for in vitro anticancer activity against different cancer cell lines HeLa (human cervical carcinoma), MIA PaCa-2 (pancreatic cancer), PANC-1(pancreatic cancer), SK-N-SH (neuroblastoma), and DU145 (prostate cancer). Compound 3g was found to be the most potent derivative among all the tested compounds against five cancer cell lines, with 50 % inhibition concentration, IC50 of 3.85±0.16, 3.75±0.32, 3.8 ± 0.13, 4.29±0.56, and 5.13±0.78 μM, respectively, with the lowest IC50 value in MIA PaCa-2 cancer cells. The exact mechanism of action of 3g was therefore investigated in MIA-PaCa-2 cells. The results show that 3g induces dose-dependent cell cycle arrest during the G2/M phase. Furthermore, downregulation of the expression of cell cycle marker proteins, such as that of cyclin B1 and Cdc25C, was found to be the reason for the termination of the G2/M phase. Furthermore, docking analysis of the promising compounds 3f, 3g, 3i, and 3j revealed the most efficient molecular interactions with the target protein cyclooxygenase-2 (PDB ID: 1CX2). Overall, 3 g could prove to be an effective agent for treating pancreatic cancer. [Display omitted] Synthesis and screening of 4-Aminoquinolines derivatives for their in vitro anticancer activity against different cancer cell lines, MIA PaCa-2, PANC-1, SK-N-SH, and DU145. Resulted 3f, 3 g, 3i and 3j was the active analogues. Among them 3 g was found to be the most potent compound.
ISSN:0022-2860
1872-8014
DOI:10.1016/j.molstruc.2024.138677